

HEALTH BOARD RISK REGISTER December 2021

(Incorporating management updates received by 14th January 2022)

RISKS ASSIGNED TO THE PERFORMANCE & FINANCE COMMITTEE

Datix ID Number: 738	HBR Ref Number: 1		t Risk Rating	
Health & Care Standard: 5.1 Timely Care Objective: Best Value Outcomes from High Quality Care	Target Date: 31st March 2022 Director Lead: Inese Robotham, Chief Operating Officer Assuring Committee: Performance and Finance Committee For information: Quality & Safety Committee Date last reviewed: December 2021			
Risk: If we fail to comply with Tier 1 target – Access to Unscheduled Care then this will have an mpact on patient and family experience. Challenges with capacity /staffing across the Health and Social care sectors.				
Risk Rating (consequence x likelihood): Initial: 4 x 5 = 20 Current: 5 x 5 = 25 Target: 3 x 4 = 12 Consequence x likelihood 25	Rationale for current score: Post wave 2 of COVID 19 Morriston and Singleton have experienced a steady increase in emergency demand to pre-covid levels. Capacity is limited due to cov response and therefore remains a high risk. Current score raised due to increasing pressures			
Level of Control = 50% Date added to the HB risk register 26.01.16 Level of Control Risk Score	Rationale for target score: Our annual plan is to implement models of care that reflect best practice. improve patient flow, length of stay and reduce emergency demand.			
Controls (What are we currently doing about the risk?)	Mitigating actions (What more should we do?)			
 Programme management office in place to improve Unscheduled Care. Daily Health Board wide conference calls/ escalation process in place. Regular reporting to Executive and Health Board/Quality and Safety Committee. Increased reporting as a result of escalation to targeted intervention status. Targeted unscheduled care investment of £8.5m in the annual plan, including a new Acute Medical Model focused on increasing ambulatory care. 	Action Joint working with WAST • Zero tolerance of over 6 hours handover delays implemented; to be brought down to 4 hours • Ambulance offload and cohorting area • Identification of patient pathways that can bypass ED	Lead Chief Operating Officer	November 2022 November 2022 December 2022	
 Development of a Phone First for ED model in conjunction with 111 to reduce demand. 24/7 ambulance triage nurse in place 	Redesign of Acute Medical Services including Same Day Emergency Care	Chief Operating Officer	December 202	
	Commissioning of up to 100 care home beds. 1st phase up to 55 beds from November 2021. 2nd phase December 2021	Chief Operating Officer	December 202	
	Establishment of 4 virtual wards aligned to GP clusters	Chief Operating Officer	December 202	
	0 !	ould we see	k?)	
Assurances (How do we know if the things we are doing are having an impact?) • New Urgent & Emergency Care Board to meet monthly	Gaps in assurance (What additional assurances shall The need to deliver sustained service.	iodia we see	,	

- Implementation of Phone First for ED as one the initiatives set out in the National Unscheduled Care Programme six goals.
- Phased implementation of the Acute Medical Services Redesign. Business case for ambulatory care element of service redesign submitted WG.

Datix ID Number: 840			Current Risk Rating		
Health & Care Standard: 5.1 Timely Care Objective: Best Value Outcomes from High Quality Care			5 x 5 = 25		
Objective. Best value Outcomes from high Quality Care		Director Lead: Inese Robotham, Chief Operating Officer			
		Assuring Committee: Performance and Finance Committee			
Risk: Access and Planned Care. There is a risk of harm to patients if we fail to diagnose and treat them in a timely way.		For information: Quality & Safety Committee Date last reviewed: December 2021			
		All non-urgent activity was cancelled due to	response to the Cov	vid-19 nandemic and	
Initial: 4 x 4 = 16	-25 25 25 25 25 25 25 25 25 25 25 25 25 2	has increased the backlog of planned care			
Current: 5 x 5 = 25		mitigating measures such as virtual clinics			
Target: 4 x 2 = 8	-12 12 12 12 12 12 12 12 12 12 12 12 12 1	still being accepted which is adding to the			
Level of Control		Ophthalmology and Orthopaedics. The significant reduction in theatre activity is			
= 90%		obviously increasing the number of patients now breaching 36 and 52 week			
		thresholds.	•		
	peril seril Merit Baril Merit purit purit seril seril octil Maril Decil	Rationale for target score: There is scope to reduce the likelihood score to reduce the Risk to an acceptable			
Date added to the HB					
risk register	Target Score Risk Score	level			
January 2013					
Contro	Is (What are we currently doing about the risk?)	Mitigating actions (What more should we do?)			
	is on minimising harm by ensuring that the patients with the high clinical	Action	Lead	Deadline	
	t. The Health Board is following the Royal College of Surgeons guidance	Implement demand management	Service Directors	31/12/2021	
- · · · · · · · · · · · · · · · · · · ·	s and patients on the waiting list have been categorised accordingly.	initiatives between primary and			
•	overy meeting for assurance on the recovery of our elective programme.	secondary care to reduce the number of			
	on specialty level capacity and demand models at specialty level that	new patients awaiting outpatient			
	city and identify solutions to bridge the gap. Non-recurring pump –	appointments.	0 . 0	00/44/0004	
	e to support initial recovery measures. Monthly performance reviews	Welsh Government has provided funding	Service Group	30/11/2021	
track progress against de		for the Health Board to develop and	Directors		
 A focused intervention is 	in train to support to the 10 specialties with the longest waits.	implement a full range of interventions to support patients to be kept active and			
		well whilst on a waiting list. The focus will			
		be on cancer patients awaiting surgery			
		and long waiting orthopaedic patients.			
Assurances (How do we kn	ow if the things we are doing are having an impact?)	Gaps in assurance (What additional ass	urances should we	seek?)	
•	place to ensure patients with greatest clinical need are treated first.	Tape in accuration (Title accuration acc	and discount in		
	Additional Comme				
	al ophthalmology day case theatre in Singleton will also be operational ear				
1 Action closed - Develop and	d implement a full range of ' treat while you wait' interventions at specialty	level to minimise harm. Two new actions a	dded.		

Datix ID Number: 1297		HBR Ref Number: 39	Current Risk Rating	g	
	fe Care 2.1 Managing Risk & Promoting Health & Safety	Target Date: 31st March 2022 4 x 4 = 16			
Objective: Demonstrating Value and Sustainability .		Director Lead: Sian Harrop-Griffiths, Director of Strategy Assuring Committee: Health Board ,Performance and Finance Committee			
Risk: Operational and strate	egic decisions are not data informed:	Date last reviewed: December 2021			
Failure to have an approvable	IMTP for 2022/23 then we will lose public confidence and breach legislation.				
		Rationale for current score:			
		Our Organisational Strategy was appro	ved by the Board in Nov	vember 2018	
Initial: 4 x 4 = 16	20 20 20 20 20 20	Quarterly and half year plans submitted			
Current: 4 x 4 = 16	16 16 16 16 16 15	The 2021/22 Annual Plan has been sub	omitted to WG on 30.06	.21 and includes a	
Target: 4 x 2 = 8		balanced financial plan.			
Level of Control	8 8 8 8 8 8 8 8 8 8 8				
= 70%					
Date added to the HB	Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ				
risk register	herit ketri Merit Kerit Merit hurit hirit kugit serit octit Merit Decit	Rationale for target score: If the IMTP is approved, it is likely our enhanced monitoring status will			
July 2017	•			atus will be	
	Target Score Risk Score	improved when next reviewed.	-		
Contr	ols (What are we currently doing about the risk?)	Mitigating actions (What more should we do?)			
 Welsh Government writt 	ten statement published on the 7 October 2020 advising that SBUHB been	Action	Lead	Deadline	
de-escalated from targe	ted intervention status to 'enhanced monitoring' status.	Development of draft Recovery and	Dir of Strategy & Dir	30/09/2021	
 A draft Annual Plan with 	in 3 year context was considered by the Board In Committee in March 2021	Sustainability Plan for approval by the	of Finance	28/02/2022	
and submitted to WG.	·	Board			
 The final Annual Plan w 	as approved by the Board on 23 June 2021 and submitted to WG on 30				
June 2021.					
 The Health Board is dev 	veloping a 3 – 5 Recovery and Sustainability Plan which will provide the				
	agreed IMTP for 2022/23.				
	ow if the things we are doing are having an impact?)	Gaps in assurance (What additional	assurances should we	seek?)	
Recovery and Sustainability V	Vorking Group has been established, chaired by CEO with independent			,	
members and Executive leads	s. The existing IMTP Executive Steering Group will provide oversight of the				
	Finance Plans assured by P&F Committee. W&OD Committee reviews the				
	tee the Q&S elements. JET meetings with WG. Robust programme				
•	in place to execute the 21/22 Annual Plan. An update on Annual plan				
progress a at Q2 was reviewe	ed by Board Nov 2021 and adjustments to off track actions approved in Dec				
		1			
Special Board.	Additional Comments				

Datix ID Number: 1563	HBR Ref Number: 48	Current Risk I	Rating	
Health & Care Standard: Safe Care 5.1 Access	Target Date: 31st March 2022 4 x 4 = 16 Director Lead: Sian Harrop-Griffiths, Director of Strategy Assuring Committee: Performance and Finance Committee, Health Board For information: Quality & Safety Committee			
Objective: Best Value Outcomes from High Quality Care				
Risk: Failure to sustain Child and Adolescent Mental Health Services	Date last reviewed: December 2021			
(consequence x likelihood): Initial: 4 x 4 = 16 Current: 4 x 4 = 16		cionale for current score: iculties with sustainable staffing affecting performance.		
Target: 4 x 2 = 8 Level of Control = 50% Date added to HB the risk register 31/05/2018	Rationale for target score: New service model and improved performance			
Controls (What are we currently doing about the risk?)	Mitigating actions (What more should we do?)			
Performance Scrutiny - is undertaken at monthly commissioning meetings between Swansea		Lead	Deadline	
Bay & Cwm Taf Morgannwg University Health Boards. Improved governance -ensures that issues and concerns are discussed by all interested parties including local authorities to support the network identify local solutions. • New Service Model agreed and being established by Summer 2019 which should give furthe	Additional investment expected - from Welsh Government	CAMHS network	31st March 2022	
stability to service.	Staffing of service being strengthened & supplemented by agency staff	CAMHS network	31st December 2021	
Assurances (How do we know if the things we are doing are having an impact?)	Gaps in assurance (What additional assurances should we se	Gaps in assurance (What additional assurances should we seek?)		
Additional Comm	ents		core stays the same.	

Datix ID Number: 1761		HBR Ref Number: 50	Current Risk Rat	ing	
Health & Care Standard: Timely Care 5.1 Access		Target Date: 31st March 2022	5 x 5 = 25		
Objective: Best Value Outcomes from High Quality Care		Director Lead: Inese Robotham, Chief Operating Officer			
		Assuring Committee: Performance and Finar	nce Committee		
		For information: Quality & Safety Committee			
Risk: Access to Cancer Services – A backlog of patients now presenting with suspected cancer has		Date last reviewed: December 2021			
	mic, creating an increase in referrals into the health board which is greater				
	rompt diagnosis and treatment. Because of this there is a risk of delay in				
	r, and consequent delay in commencement of treatment, which could lead				
to poor patient outcomes and t	ailure to achieve targets.				
Risk Rating		Rationale for current score:			
(consequence x likelihood):	-25 25 25 25 25 25 25 25 25 25 25 25 25 2	There has been a reduction in presentation and			
Initial: $4 \times 5 = 20$	20 20	backlog has increased and treatment times have got longer due to Covid-19 relat			
Current: $5 \times \frac{45}{45} = \frac{20}{25}$		reductions in surgical capacity. Enhanced mor			
Target: 4 x 3 = 12	-12 12 12 12 12 12 12 12 12 12 12 12 12 1	plans for top 6 tumour sites in place. Risk score	e updated based on be	ing off	
		trajectory for SCP and Backlog increasing.			
Level of Control	particle of the particle of th	Rationale for target score: Target score reflects the challenge this area of work present the Board and whe			
= 70%					
	isy, ten they be, they in, in, bine ten oc, to, de,			a ana wnere	
Date added to the HB risk		small numbers of patients impact on the potent		a and where	
Date added to the HB risk register	Target Score Risk Score			a ana wnere	
Date added to the HB risk register April 2014	——Target Score ——Risk Score	small numbers of patients impact on the potent	tial to breach target	a and wnere	
Date added to the HB risk register April 2014 Contro	Target Score ——Risk Score Is (What are we currently doing about the risk?)	small numbers of patients impact on the potent Mitigating actions (What mo	tial to breach target ore should we do?)		
Date added to the HB risk register April 2014 Contro Tight management processes	Target Score Risk Score Is (What are we currently doing about the risk?) to manage each individual case on the Urgent Suspected Cancer	small numbers of patients impact on the potent Mitigating actions (What mo	ore should we do?) Lead	Deadling	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir	Target Score —Risk Score Is (What are we currently doing about the risk?) to manage each individual case on the Urgent Suspected Cancering & weekly monitoring of action plans for top 6 tumour sites.	Mitigating actions (What mo	ore should we do?) Lead Service Group	Deadling	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir Initiatives to protect surgical care	Is (What are we currently doing about the risk?) to manage each individual case on the Urgent Suspected Cancering & weekly monitoring of action plans for top 6 tumour sites. apacity to support USC pathways have been put in place	Mitigating actions (What months) Action Phased and sustainable solution for the required uplift in endoscopy capacity that will	ore should we do?) Lead	Deadling 4st November	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir Initiatives to protect surgical ca	Is (What are we currently doing about the risk?) to manage each individual case on the Urgent Suspected Cancer ng & weekly monitoring of action plans for top 6 tumour sites. apacity to support USC pathways have been put in place coordinators, with cancer trackers appointed in April 2021.	Mitigating actions (What months) Action Phased and sustainable solution for the required uplift in endoscopy capacity that will be key to supporting both the Urgent	ore should we do?) Lead Service Group	Deadlin 1st Novembe 2021	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir Initiatives to protect surgical ca Additional investment in MDT Prioritised pathway in place to	Is (What are we currently doing about the risk?) to manage each individual case on the Urgent Suspected Cancer are & weekly monitoring of action plans for top 6 tumour sites. apacity to support USC pathways have been put in place coordinators, with cancer trackers appointed in April 2021. fast track USC patients.	Mitigating actions (What monoton) Action Phased and sustainable solution for the required uplift in endoscopy capacity that will be key to supporting both the Urgent Suspected Cancer backlog and future cancer	ore should we do?) Lead Service Group	Deadling 1st November 2021	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir Initiatives to protect surgical ca Additional investment in MDT Prioritised pathway in place to Ongoing comprehensive dema	Is (What are we currently doing about the risk?) It to manage each individual case on the Urgent Suspected Cancering & weekly monitoring of action plans for top 6 tumour sites. In apacity to support USC pathways have been put in place coordinators, with cancer trackers appointed in April 2021. If ast track USC patients. In and and capacity analysis with directorates to maximise efficiencies. This	Mitigating actions (What monoton) Action Phased and sustainable solution for the required uplift in endoscopy capacity that will be key to supporting both the Urgent Suspected Cancer backlog and future cancer diagnostic demand on Endoscopy Services.	cre should we do?) Lead Service Group Manager	Deadlin 1st Novembe 2021 01 Aug 22	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir Initiatives to protect surgical canditional investment in MDT Prioritised pathway in place to Ongoing comprehensive dema	Is (What are we currently doing about the risk?) to manage each individual case on the Urgent Suspected Cancer ng & weekly monitoring of action plans for top 6 tumour sites. apacity to support USC pathways have been put in place coordinators, with cancer trackers appointed in April 2021. fast track USC patients. and and capacity analysis with directorates to maximise efficiencies. This e Cancer Performance Group.	Mitigating actions (What monoton) Action Phased and sustainable solution for the required uplift in endoscopy capacity that will be key to supporting both the Urgent Suspected Cancer backlog and future cancer	cre should we do?) Lead Service Group Manager Cancer Quality &	Deadlin 1st Novembe 2021 01 Aug 22	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir Initiatives to protect surgical ca Additional investment in MDT Prioritised pathway in place to Ongoing comprehensive dema will form part of the remit of the Weekly cancer performance in	Is (What are we currently doing about the risk?) It to manage each individual case on the Urgent Suspected Cancering & weekly monitoring of action plans for top 6 tumour sites. In apacity to support USC pathways have been put in place coordinators, with cancer trackers appointed in April 2021. If ast track USC patients. In and and capacity analysis with directorates to maximise efficiencies. This	Mitigating actions (What months) Action Phased and sustainable solution for the required uplift in endoscopy capacity that will be key to supporting both the Urgent Suspected Cancer backlog and future cancer diagnostic demand on Endoscopy Services. Harm review process to be implemented.	cre should we do?) Lead Service Group Manager Cancer Quality & Standards Manager	Deadline 4st November 2021 01 Aug 22 31 Jan 22	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir Initiatives to protect surgical ca Additional investment in MDT Prioritised pathway in place to Ongoing comprehensive dema will form part of the remit of the Weekly cancer performance in specialty.	Is (What are we currently doing about the risk?) It to manage each individual case on the Urgent Suspected Cancering & weekly monitoring of action plans for top 6 tumour sites. In apacity to support USC pathways have been put in place coordinators, with cancer trackers appointed in April 2021. If ast track USC patients. In and and capacity analysis with directorates to maximise efficiencies. This is a Cancer Performance Group. In	Mitigating actions (What monoton) Action Phased and sustainable solution for the required uplift in endoscopy capacity that will be key to supporting both the Urgent Suspected Cancer backlog and future cancer diagnostic demand on Endoscopy Services. Harm review process to be implemented. Establishment of HB Cancer Performance	cre should we do?) Lead Service Group Manager Cancer Quality &	Deadline 4st November 2021 01 Aug 22 31 Jan 22	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir Initiatives to protect surgical ca Additional investment in MDT Prioritised pathway in place to Ongoing comprehensive dema will form part of the remit of the Weekly cancer performance in specialty.	Is (What are we currently doing about the risk?) to manage each individual case on the Urgent Suspected Cancer ng & weekly monitoring of action plans for top 6 tumour sites. apacity to support USC pathways have been put in place coordinators, with cancer trackers appointed in April 2021. fast track USC patients. and and capacity analysis with directorates to maximise efficiencies. This e Cancer Performance Group.	Mitigating actions (What months) Action Phased and sustainable solution for the required uplift in endoscopy capacity that will be key to supporting both the Urgent Suspected Cancer backlog and future cancer diagnostic demand on Endoscopy Services. Harm review process to be implemented.	cre should we do?) Lead Service Group Manager Cancer Quality & Standards Manager	Deadline 4st November 2021 01 Aug 22 31 Jan 22	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir Initiatives to protect surgical canditional investment in MDT Prioritised pathway in place to Ongoing comprehensive demawill form part of the remit of the Weekly cancer performance in specialty. The tumour sites of concern is	Is (What are we currently doing about the risk?) It to manage each individual case on the Urgent Suspected Cancering & weekly monitoring of action plans for top 6 tumour sites. In apacity to support USC pathways have been put in place coordinators, with cancer trackers appointed in April 2021. If ast track USC patients. In and and capacity analysis with directorates to maximise efficiencies. This is a Cancer Performance Group. In	Mitigating actions (What monoton) Action Phased and sustainable solution for the required uplift in endoscopy capacity that will be key to supporting both the Urgent Suspected Cancer backlog and future cancer diagnostic demand on Endoscopy Services. Harm review process to be implemented. Establishment of HB Cancer Performance Group	cre should we do?) Lead Service Group Manager Cancer Quality & Standards Manager Deputy COO	Deadling 1st November 2021 01 Aug 22 31 Jan 22 Complete	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir Initiatives to protect surgical canditional investment in MDT Prioritised pathway in place to Ongoing comprehensive demawill form part of the remit of the Weekly cancer performance in specialty. The tumour sites of concern is increased by 4 times in April.	Is (What are we currently doing about the risk?) to manage each individual case on the Urgent Suspected Cancer ng & weekly monitoring of action plans for top 6 tumour sites. apacity to support USC pathways have been put in place coordinators, with cancer trackers appointed in April 2021. fast track USC patients. and and capacity analysis with directorates to maximise efficiencies. This cancer Performance Group. neetings are held for both NPTS and Morriston Service Groups by in development. One of the areas is Lower GI where clinic capacity has	Mitigating actions (What monocomplements) Mitigating actions (What monocomplements) Action Phased and sustainable solution for the required uplift in endoscopy capacity that will be key to supporting both the Urgent Suspected Cancer backlog and future cancer diagnostic demand on Endoscopy Services. Harm review process to be implemented. Establishment of HB Cancer Performance Group Work programme for HB Cancer	cre should we do?) Lead Service Group Manager Cancer Quality & Standards Manager	Deadling 1st November 2021 01 Aug 22 31 Jan 22 Complete	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir Initiatives to protect surgical ca Additional investment in MDT Prioritised pathway in place to Ongoing comprehensive dema will form part of the remit of the Weekly cancer performance in specialty. The tumour sites of concern is increased by 4 times in April. plans.	Is (What are we currently doing about the risk?) to manage each individual case on the Urgent Suspected Cancer ng & weekly monitoring of action plans for top 6 tumour sites. apacity to support USC pathways have been put in place coordinators, with cancer trackers appointed in April 2021. fast track USC patients. and and capacity analysis with directorates to maximise efficiencies. This e Cancer Performance Group. neetings are held for both NPTS and Morriston Service Groups by in development. One of the areas is Lower GI where clinic capacity has The top 6 tumour sites of concern have developed. Cancer improvement	Mitigating actions (What monoton) Action Phased and sustainable solution for the required uplift in endoscopy capacity that will be key to supporting both the Urgent Suspected Cancer backlog and future cancer diagnostic demand on Endoscopy Services. Harm review process to be implemented. Establishment of HB Cancer Performance Group	cre should we do?) Lead Service Group Manager Cancer Quality & Standards Manager Deputy COO	Deadline 4st November 2021 01 Aug 22 31 Jan 22 30 Nov 21 Complete	
Date added to the HB risk register April 2014 Contro Tight management processes Pathway. Enhanced monitorir Initiatives to protect surgical ca Additional investment in MDT Prioritised pathway in place to Ongoing comprehensive dema will form part of the remit of the Weekly cancer performance in specialty. The tumour sites of concern is increased by 4 times in April. plans.	Is (What are we currently doing about the risk?) to manage each individual case on the Urgent Suspected Cancering & weekly monitoring of action plans for top 6 tumour sites. apacity to support USC pathways have been put in place coordinators, with cancer trackers appointed in April 2021. fast track USC patients. and and capacity analysis with directorates to maximise efficiencies. This is a Cancer Performance Group. The etings are held for both NPTS and Morriston Service Groups by the in development. One of the areas is Lower GI where clinic capacity has the top 6 tumour sites of concern have developed. Cancer improvement the service of diagnostic recovery and theatre recovery workstreams.	Mitigating actions (What monocomplements) Mitigating actions (What monocomplements) Action Phased and sustainable solution for the required uplift in endoscopy capacity that will be key to supporting both the Urgent Suspected Cancer backlog and future cancer diagnostic demand on Endoscopy Services. Harm review process to be implemented. Establishment of HB Cancer Performance Group Work programme for HB Cancer	cre should we do?) Lead Service Group Manager Cancer Quality & Standards Manager Deputy COO	Deadline 4st November 2021 01 Aug 22 31 Jan 22	

Assurances (How do we know if the things we are doing are having an impact?)

Backlog trajectory accepted at Management Board on 15th September and trajectory will be monitored in weekly enhanced monitoring meetings. Cancer Performance Group being established to support execution of the services delivery plans for improvements.

Gaps in assurance (What additional assurances should we seek?)

Clear current funding gap.

Performance and activity data monitored, but delays to treatment continue while sustainable solutions found.

Additional Comments

18.11.21 In September, the HB reported 62% compliance, meeting the trajectory of 62%. Total waits at all stages pre-treatment show a level of stability through September, showing a small decline through October but remain considerably higher than at any other point since the start of 2020 and 44% higher than January 2021.


We are still experiencing the impact and restrictions of COVID-19 on our services and our cancer pathways. The number of COVID patients being admitted into our hospitals has increased significantly through July and August. End of October Backlog remains off trajectory by+61


Actions updated to more accurately reflect actions directly related to this risk including the new established Cancer Performance Group. Risk score updated based on being off trajectory for SCP and Backlog. Controls updated to accurately reflect work being undertaken.

12.01.21: Weekly operational tumour site meetings continue with top 7 sites. Challenge and review of data done by CIT and Cancer Associate Service Group Director for Cancer Division. Cancer Improvement Group has now been stood down, new Cancer Programme Board to be established and chaired by Medical Director. PMO office to be engaged to support set up of programme and programme board. Draft TOR for this new Cancer Programme Board (PBD) have been complete and were approved in last CIG.

The newly established Cancer Programme Group chaired by Deputy COO will report into this Cancer Programme Board.

		HBR Ref Number: 52	Current Ris	k Rating	
		Target Date: 31st March 2022	4 x 3 = 12		
Objective: Partnerships for Care – Effective Governance		Director Lead: Sian Harrop-Griffiths, Director of Strategy			
		Assuring Committee: Performance and	d Finance Committee		
	not have sufficient resource in place to undertake engagement & impact	Date last reviewed: December 2021			
assessment in line with strate	gic service change				
Risk Rating		Rationale for current score:			
consequence x likelihood):		Current lack of sustainable funding	source to secure cap	acity	
Initial: 4 x 4 = 16					
Current: 4 x 3 = 12					
Target: 4 x 2 = 8	-12 12 12 12 12 12 12 12 12 12 12 12 12 1				
Level of Control	8 8 8 8 8 8 8 8 8 8	Rationale for target score:			
	= 50%		All of these areas need to have adequate resourcing and robust processes /		
Date added to the HB		policies in place for the organisation to make robust plans, engage public confidence and meet our statutory and public duties.			
risk register	ighted feeten Water Water Manuel Mitter Water Search Octob Mount Decept				
November 2018	Target Score Risk Score				
Contro	ls (What are we currently doing about the risk?)	Mitigating actions (What more should we do?)			
Band 6 recruited to provide		Action	Lead	Deadline	
	ent & Partnerships appointed to provide additional support for	Conclude work on exec equalities	Interim Assistant	31st December 2021	
engagement.		portfolios	Director of		
• •	ses to be in place for Impact Assessment going forward.		Strategy		
	rated into planning roles going forward.		3		
·					
Consideration being given	o temporary support.				
Assurances (How do we kn	ow if the things we are doing are having an impact?)	Gaps in assurance (What additional a	ssurances should v	ve seek?)	
	rice and support to be considered as part of resourcing for engagement.	Permanent additional resources not yet available			
	Additional Comm				





Objective: Best Value Outcome	Datix ID Number: 2739 Health & Care Standard: 2.1.1 Managing Financial Risk Objective: Best Value Outcomes from High Quality Care Risk: The COVID-19 pandemic has services in many different ways, in this risk specifically the		HBR Ref Number: 79 Target Date: 31st March 2022 Director Lead: Darren Griffiths. Director of Finance Assuring Committee: Performance and Finance Committee			
impact on access to services, such as OP, diagnostic tests, IP&DC and therapy services. The recovery of access times will require additional human, estates and financial resource to support it. There is potential for resource available is below the ambition of the board to provide improved		Date last reviewed: December 2021				
Risk Rating (consequence x likelihood): Initial: 5 x 3 = 15 Current: 5 x 3 = 15 Target: 5 x 1 = 5 Level of Control = 25% Date added to the HB risk register May 2021	Risk Rating (consequence x likelihood): Initial: 5 x 3 = 15 Current: 5 x 3 = 15 Target: 5 x 1 = 5 Level of Control = 25% Date added to the HB risk register Risk Score Risk Rating (consequence x likelihood): Initial: 5 x 3 = 15 Target: 5 x 3 = 15 Target: 5 x 1 = 5 Level of Control = 25% Date added to the HB risk register		 Rationale for current score: Significant backlog for patients to access across elective and cancer care in the following areas, diagnostics, OP, IP&DC, therapy, Oncology Welsh Government has set aside resource for the recovery of the health system with the areas above a clear area of focus. The Health Board has submitted bids against a first tranche of funding available from Welsh Government but this is not yet allocated Score reflects the high impact of not being able to address the access backlog due to affordability reasons, whilst the likelihood is 3 as resource is anticipated Rationale for target score: Securing resources to meet the ambition of the Health Board in terms of access recovery will recue this risk which is an affordability, rather than a service delivery risk. 			
Controls	(What are we currently doing about the risk?)	Mitigating actions (What more should we do?)				
The Health Board is doing the f	G	Action	Lead	Deadline		
 Working with specialists to develop plans to maximise Health Board capacity safely and within extant COVID guidelines Developing more advanced service models to test scenarios to allow for accurate demand and capacity plans to be developed Working with Welsh Government to access additional funding based on the modelling carried out to date Ensuring that financial controls are in place to enable swift decisions to be made on allocation of additional resource but also ensuring that the commitment made do not exceed the allocation sum (when known) Transparent reporting to Performance and Finance Committee and Quality and Safety Committee on progress and plan development. 		Develop a final annual plan setting out recovery plans	Director of Finance and Director of Strategy	23 rd July 2021		
		Prioritise limited Health Board internal capacity and resource in a risk assessed way.	Chief Operating Officer	30 th July 2021 Monthly ongoing		

Assurances

(How do we know if the things we are doing are having an impact?)

The Health Board financial performance is reviewed and monitored through:

- Monthly financial recovery meetings
- Performance and Finance Committee
- Routine reporting to Board of most recent monthly position and availability of national funding support recovery

Gaps in assurance

(What additional assurances should we seek?)

Management of access is prioritised based on clinical risk management.

Additional Comments

Datix ID Number: 2554 *NEW RISK*			ent Risk Rating	
Health & Care Standard: Standard 5.1 Timely Access Objective: Best Value Outcomes from High Quality Care		311 111	5 = 25	
		Director Lead: Executive Medical Director Assuring Committee: Performance & Finance Committee For Information: Workforce & OD Committee		
There is a risk that adequate Buclosure to this regional service and Decreasing consultant num Anaesthetists not gaining Concourage local developments Other UK burns units have ICU	CT with appropriate ICM and Burns experience, despite attempts to	Date last reviewed: January 2022		
Consultants. Risk Rating (consequence x likelihood): Initial: 4 x 3 = 12 Current: 5 x 5 = 25 Target: 3 x 1 = 3 Level of Control = Date added to the HB risk register Date added to the HB risk register		Rationale for current score: This risk has been increased due to closure of Rationale for target score: This is a small clinical service with staff with hig services may always be vulnerable to challenge operate a more resilient clinical model that is so	hly specialised skills s (eg staff) the intel	s. While a small ntion will be to
Controls	Target Score —Risk Score	Mission stinus (Miles)	ana alaanid oo da	2)
	(What are we currently doing about the risk?)	Mitigating actions (What r	Lead	<u>r)</u> Deadline
 Currently have 8 consultants in post - managing sickness and job planning process to sustain existing consultant workforce as far as possible. 		TBC – There are ongoing discussions looking a how the risk is mitigated and the service maintained		TBC
Assurances (How do we know if the things we are doing are having an impact?) Effect on patients of the temporary closure of the burns service in Swansea is being mitigated by maintaining an urgent assessment/stabilisation service for patients in Wales with severe burns, with onward transfer for inpatient care to another unit in the UK following the initial assessment		Gaps in assurance (What additional assuran	ces should we see	ek?)

Ongoing staff burnout combined with two substantive consultants resigning means there is no foreseeable mechanism to open the burns unit as it previously operated. Have recurrently advertised with no applicants and initial efforts for oversee recruitment not successful.

November 2021: Burns service currently closed to P3 patients; P2 patients located in Wales will be assessed before transfer to another unit or downgrade to ward based patient; WG notified via NSA – November 2021

Risk Score Calculation

For each risk identified, the LIKELIHOOD & CONSEQUENCE mechanism will be utilised. Essentially this examines each of the risks and attempts to assess the likelihood of the event occurring (PROBABLILITY) and the effect it could have on the Health Board (IMPACT). This process ensures that the Health Board will be focusing on those risks which require immediate attention rather than spending time on areas which are, relatively, a lower priority.

Risk Matrix	LIKELIHOOD (*)				
CONSEQUENCE (**)	1 - Rare	2 - Unlikely	3 - Possible	4 - Probable	5 - Expected
1 - Negligible	1	2	3	4	5
2 - Minor	2	4	6	8	10
3 - Moderate	3	6	9	12	15
4 - Major	4	8	12	16	20
5 - Catastrophic	5	10	15	20	25